Journal
MOLECULAR NEUROBIOLOGY
Volume 54, Issue 3, Pages 1967-1977Publisher
SPRINGER
DOI: 10.1007/s12035-016-9802-9
Keywords
Alzheimer's disease (AD); beta-Site amyloid precursor protein cleavage enzyme 1 ( BACE1); Curcumin; beta-Amyloid protein ( A beta)
Categories
Funding
- National Natural Science Foundation of China [91232709, 811171216, 81110555, 81401149]
- National and Fujian Province's Key Clinical Specialty Discipline Construction Programs
Ask authors/readers for more resources
Alzheimer's disease (AD) is the most common dementia and the trigger of its pathological cascade is widely believed to be the overproduction and accumulation of beta-amyloid protein (A beta) in the affected brain. However, effective AD remedies are still anxiously awaited. Recent evidence suggests that curcumin may be a potential agent for AD treatment. In this study, we used 5xFAD transgenic mice as an AD model to investigate the effects of curcumin on AD. Our results showed that curcumin administration (150 or 300 mg/kg/day, intragastrically, for 60 days) dramatically reduced A beta production by downregulating BACE1 expression, preventing synaptic degradation, and improving spatial learning and memory impairment of 5xFAD mice. These findings suggest that curcumin is a potential candidate for AD treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available